3 Biotechs Generating a Lot Of Buzz
This should be a busy week as there are several healthcare events taking place. Three stocks that investors should keep their eyes on are Arrowhead Research Corporation (NASDAQ:ARWR), Celgene Corporation (NASDAQ:CELG), and Clovis Oncology (NASDAQ:CLVS).
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. The company’s lead product is ARC-520 which is being evaluated for the treatment of Hepatitis B. It is currently in Phase I testing. The company is also evaluating ARC-520 for the potential treatment of Liver Targets and Extra-Hepatic. Both of these studies are in the pre-clinical stage.
Shares of Arrowhead Research have seen a dramatic rise over the past two trading sessions, increasing by more than 10 percent as of this writing. The company got a big bump today after the weekend announcement that Alnylam Pharmaceuticals (NASDAQ:ALNY) and Genzyme would form a transformational alliance for RNAi therapeutics as genetic medicines. Although this deal specifically benefits Alnylam Pharmaceuticals and Genzyme, Arrowhead Research should participate in the RNAi rally which is sure to continue because of its incredible potential.